Therefore, it was hypothesized that inflammatory markers, such as CRP, ILs, tumor-infiltrating neutrophils and lymphocytes, and platelets, might be potential indicators for predicting the response of patients with mPC to mFOLFIRINOX. This evidence concerns the gene CRP and neoplasm.